Triaxially deformed relativistic point-coupling model for Λ\Lambda hypernuclei: a quantitative analysis of hyperon impurity effect on nuclear collective properties

The impurity effect of hyperon on atomic nuclei has received a renewed interest in nuclear physics since the first experimental observation of appreciable reduction of $E2$ transition strength in low-lying states of hypernucleus $^{7}_\Lambda$Li. Many more data on low-lying states of $\Lambda$ hypernuclei will be measured soon for $sd$-shell nuclei, providing good opportunities to study the $\Lambda$ impurity effect on nuclear low-energy excitations. We carry out a quantitative analysis of $\Lambda$ hyperon impurity effect on the low-lying states of $sd$-shell nuclei at the beyond-mean-field level based on a relativistic point-coupling energy density functional (EDF), considering that the $\Lambda$ hyperon is injected into the lowest positive-parity ($\Lambda_s$) and negative-parity ($\Lambda_p$) states. We adopt a triaxially deformed relativistic mean-field (RMF) approach for hypernuclei and calculate the $\Lambda$ binding energies of hypernuclei as well as the potential energy surfaces (PESs) in $(\beta, \gamma)$ deformation plane. We also calculate the PESs for the $\Lambda$ hypernuclei with good quantum numbers using a microscopic particle rotor model (PRM) with the same relativistic EDF. The triaxially deformed RMF approach is further applied in order to determine the parameters of a five-dimensional collective Hamiltonian (5DCH) for the collective excitations of triaxially deformed core nuclei. Taking $^{25,27}_{\Lambda}$Mg and $^{31}_{\Lambda}$Si as examples, we analyse the impurity effects of $\Lambda_s$ and $\Lambda_p$ on the low-lying states of the core nuclei...Comment: 15 pages with 18 figures and 1 table (version to be published in Physical Review C

Doublecortin-Expressing Cells Persist in the Associative Cerebral Cortex and Amygdala in Aged Nonhuman Primates

A novel population of cells that express typical immature neuronal markers including doublecortin (DCX+) has been recently identified throughout the adult cerebral cortex of relatively large mammals (guinea pig, rabbit, cat, monkey and human). These cells are more common in the associative relative to primary cortical areas and appear to develop into interneurons including type II nitrinergic neurons. Here we further describe these cells in the cerebral cortex and amygdala, in comparison with DCX+ cells in the hippocampal dentate gyrus, in three age groups of rhesus monkeys: young adult (12.3 ± 0.2 years, n = 3), mid-age (21.2 ± 1.9 years, n = 3) and aged (31.3 ± 1.8 years, n = 4). DCX+ cells with a heterogeneous morphology persisted in layers II/III primarily over the associative cortex and amygdala in all groups (including in two old animals with cerebral amyloid pathology), showing a parallel decline in cell density with age across regions. In contrast to the cortex and amygdala, DCX+ cells in the subgranular zone diminished in the mid-age and aged groups. DCX+ cortical cells might arrange as long tangential migratory chains in the mid-age and aged animals, with apparently distorted cell clusters seen in the aged group. Cortical DCX+ cells colocalized commonly with polysialylated neural cell adhesion molecule and partially with neuron-specific nuclear protein and γ-aminobutyric acid, suggesting a potential differentiation of these cells into interneuron phenotype. These data suggest a life-long role for immature interneuron-like cells in the associative cerebral cortex and amygdala in nonhuman primates

A Systematic Analysis of Fe II Emission in Quasars: Evidence for Inflow to the Central Black Hole

Broad Fe II emission is a prominent feature of the optical and ultraviolet spectra of quasars. We report on a systematical investigation of optical Fe II emission in a large sample of 4037 z < 0.8 quasars selected from the Sloan Digital Sky Survey. We have developed and tested a detailed line-fitting technique, taking into account the complex continuum and narrow and broad emission-line spectrum. Our primary goal is to quantify the velocity broadening and velocity shift of the Fe II spectrum in order to constrain the location of the Fe II-emitting region and its relation to the broad-line region. We find that the majority of quasars show Fe II emission that is redshifted, typically by ~ 400 km/s but up to 2000 km/s, with respect to the systemic velocity of the narrow-line region or of the conventional broad-line region as traced by the Hbeta line. Moreover, the line width of Fe II is significantly narrower than that of the broad component of Hbeta. We show that the magnitude of the Fe II redshift correlates inversely with the Eddington ratio, and that there is a tendency for sources with redshifted Fe II emission to show red asymmetry in the Hbeta line. These characteristics strongly suggest that Fe II originates from a location different from, and most likely exterior to, the region that produces most of Hbeta. The Fe II-emitting zone traces a portion of the broad-line region of intermediate velocities whose dynamics may be dominated by infall.Comment: 20 pages, 14 figures, accepted for publication in Ap

A Modified Scalar-Tensor-Vector Gravity Theory and the Constraint on its Parameters

A gravity theory called scalar-tensor-vector gravity (STVG) has been recently developed and succeeded in solar system, astrophysical and cosmological scales without dark matter [J. W. Moffat, J. Cosmol. Astropart. Phys. 03, 004 (2006)]. However, two assumptions have been used: (i) $B(r)=A^{-1}(r)$, where $B(r)$ and $A(r)$ are $g_{00}$ and $g_{rr}$ in the Schwarzschild coordinates (static and spherically symmetric); (ii) scalar field $G=Const.$ in the solar system. These two assumptions actually imply that the standard parametrized post-Newtonian parameter $\gamma=1$. In this paper, we relax these two assumptions and study STVG further by using the post-Newtonian (PN) approximation approach. With abandoning the assumptions, we find $\gamma\neq1$ in general cases of STVG. Then, a version of modified STVG (MSTVG) is proposed through introducing a coupling function of scalar field G: $\theta(G)$. We have derived the metric and equations of motion (EOM) in 1PN for general matter without specific equation of state and $N$ point masses firstly. Subsequently, the secular periastron precession $\dot{\omega}$ of binary pulsars in harmonic coordinates is given. After discussing two PPN parameters ($\gamma$ and $\beta$) and two Yukawa parameters ($\alpha$ and $\lambda$), we use $\dot{\omega}$ of four binary pulsars data (PSR B1913+16, PSR B1534+12, PSR J0737-3039 and PSR B2127+11C) to constrain the Yukawa parameters for MSTVG: $\lambda=(3.97\pm0.01)\times10^{8}$m and $\alpha=(2.40\pm0.02)\times10^{-8}$ if we fix $|2\gamma-\beta-1|=0$.Comment: 39 pages, 4 figures, accepted by PR

Bi-Large Neutrino Mixing See-Saw Mass Matrix with Texture Zeros and Leptogenesis

We study constraints on neutrino properties from texture zeros in bi-large mixing See-Saw mass matrix and also from leptogenesis. Texture zeros may occur in the light (class a)) or in the heavy (class b)) neutrino mass matrices. Each of these two classes has 5 different forms which can produce non-trivial three generation mixing with at least one texture zero. We find that two types of texture zero mass matrices in both class a) and class b) can be consistent with present data on neutrino masses, mixing and produce the observed baryon asymmetry of the universe. None of the neutrinos can have zero masses with the lightest of the light neutrinos having a mass larger than about 0.039 eV for class a) and 0.002 eV for class b). In these models although CKM CP violating phase vanishes, non-zero Majorana phases, however, can exist and play an important role in producing the observed baryon asymmetry in our universe through leptogenesis mechanism. The requirement of producing the observed baryon asymmetry can further distinguish different models and also restrict the See-Saw scale to be in the range $10^{12}\sim 10^{15}$ GeV.Comment: 21 pages, 7 figures revised version, some references added, to be submitted to PR

Risk of myocarditis following sequential doses of COVID-19 vaccine and SARS-CoV-2 infection by age and sex

Myocarditis is more common after severe acute respiratory syndrome coronavirus 2 infection than after COVID-19 vaccination, but the risks in younger people and after sequential vaccine doses are less certain. METHODS: A self-controlled case series study of people ages 13 years or older vaccinated for COVID-19 in England between December 1, 2020, and December 15, 2021, evaluated the association between vaccination and myocarditis, stratified by age and sex. The incidence rate ratio and excess number of hospital admissions or deaths from myocarditis per million people were estimated for the 1 to 28 days after sequential doses of adenovirus (ChAdOx1) or mRNA-based (BNT162b2, mRNA-1273) vaccines, or after a positive SARS-CoV-2 test. RESULTS: In 42 842 345 people receiving at least 1 dose of vaccine, 21 242 629 received 3 doses, and 5 934 153 had SARS-CoV-2 infection before or after vaccination. Myocarditis occurred in 2861 (0.007%) people, with 617 events 1 to 28 days after vaccination. Risk of myocarditis was increased in the 1 to 28 days after a first dose of ChAdOx1 (incidence rate ratio, 1.33 [95% CI, 1.09–1.62]) and a first, second, and booster dose of BNT162b2 (1.52 [95% CI, 1.24–1.85]; 1.57 [95% CI, 1.28–1.92], and 1.72 [95% CI, 1.33–2.22], respectively) but was lower than the risks after a positive SARS-CoV-2 test before or after vaccination (11.14 [95% CI, 8.64–14.36] and 5.97 [95% CI, 4.54–7.87], respectively). The risk of myocarditis was higher 1 to 28 days after a second dose of mRNA-1273 (11.76 [95% CI, 7.25–19.08]) and persisted after a booster dose (2.64 [95% CI, 1.25–5.58]). Associations were stronger in men younger than 40 years for all vaccines. In men younger than 40 years old, the number of excess myocarditis events per million people was higher after a second dose of mRNA-1273 than after a positive SARS-CoV-2 test (97 [95% CI, 91–99] versus 16 [95% CI, 12–18]). In women younger than 40 years, the number of excess events per million was similar after a second dose of mRNA-1273 and a positive test (7 [95% CI, 1–9] versus 8 [95% CI, 6–8]). CONCLUSIONS: Overall, the risk of myocarditis is greater after SARS-CoV-2 infection than after COVID-19 vaccination and remains modest after sequential doses including a booster dose of BNT162b2 mRNA vaccine. However, the risk of myocarditis after vaccination is higher in younger men, particularly after a second dose of the mRNA-1273 vaccine

Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study.

ObjectiveTo assess the association between covid-19 vaccines and risk of thrombocytopenia and thromboembolic events in England among adults.DesignSelf-controlled case series study using national data on covid-19 vaccination and hospital admissions.SettingPatient level data were obtained for approximately 30 million people vaccinated in England between 1 December 2020 and 24 April 2021. Electronic health records were linked with death data from the Office for National Statistics, SARS-CoV-2 positive test data, and hospital admission data from the United Kingdom's health service (NHS).Participants29 121 633 people were vaccinated with first doses (19 608 008 with Oxford-AstraZeneca (ChAdOx1 nCoV-19) and 9 513 625 with Pfizer-BioNTech (BNT162b2 mRNA)) and 1 758 095 people had a positive SARS-CoV-2 test. People aged ≥16 years who had first doses of the ChAdOx1 nCoV-19 or BNT162b2 mRNA vaccines and any outcome of interest were included in the study.Main outcome measuresThe primary outcomes were hospital admission or death associated with thrombocytopenia, venous thromboembolism, and arterial thromboembolism within 28 days of three exposures: first dose of the ChAdOx1 nCoV-19 vaccine; first dose of the BNT162b2 mRNA vaccine; and a SARS-CoV-2 positive test. Secondary outcomes were subsets of the primary outcomes: cerebral venous sinus thrombosis (CVST), ischaemic stroke, myocardial infarction, and other rare arterial thrombotic events.ResultsThe study found increased risk of thrombocytopenia after ChAdOx1 nCoV-19 vaccination (incidence rate ratio 1.33, 95% confidence interval 1.19 to 1.47 at 8-14 days) and after a positive SARS-CoV-2 test (5.27, 4.34 to 6.40 at 8-14 days); increased risk of venous thromboembolism after ChAdOx1 nCoV-19 vaccination (1.10, 1.02 to 1.18 at 8-14 days) and after SARS-CoV-2 infection (13.86, 12.76 to 15.05 at 8-14 days); and increased risk of arterial thromboembolism after BNT162b2 mRNA vaccination (1.06, 1.01 to 1.10 at 15-21 days) and after SARS-CoV-2 infection (2.02, 1.82 to 2.24 at 15-21 days). Secondary analyses found increased risk of CVST after ChAdOx1 nCoV-19 vaccination (4.01, 2.08 to 7.71 at 8-14 days), after BNT162b2 mRNA vaccination (3.58, 1.39 to 9.27 at 15-21 days), and after a positive SARS-CoV-2 test; increased risk of ischaemic stroke after BNT162b2 mRNA vaccination (1.12, 1.04 to 1.20 at 15-21 days) and after a positive SARS-CoV-2 test; and increased risk of other rare arterial thrombotic events after ChAdOx1 nCoV-19 vaccination (1.21, 1.02 to 1.43 at 8-14 days) and after a positive SARS-CoV-2 test.ConclusionIncreased risks of haematological and vascular events that led to hospital admission or death were observed for short time intervals after first doses of the ChAdOx1 nCoV-19 and BNT162b2 mRNA vaccines. The risks of most of these events were substantially higher and more prolonged after SARS-CoV-2 infection than after vaccination in the same population

AluScan: a method for genome-wide scanning of sequence and structure variations in the human genome

<p>Abstract</p> <p>Background</p> <p>To complement next-generation sequencing technologies, there is a pressing need for efficient pre-sequencing capture methods with reduced costs and DNA requirement. The Alu family of short interspersed nucleotide elements is the most abundant type of transposable elements in the human genome and a recognized source of genome instability. With over one million Alu elements distributed throughout the genome, they are well positioned to facilitate genome-wide sequence amplification and capture of regions likely to harbor genetic variation hotspots of biological relevance.</p> <p>Results</p> <p>Here we report on the use of inter-Alu PCR with an enhanced range of amplicons in conjunction with next-generation sequencing to generate an Alu-anchored scan, or 'AluScan', of DNA sequences between Alu transposons, where Alu consensus sequence-based 'H-type' PCR primers that elongate outward from the head of an Alu element are combined with 'T-type' primers elongating from the poly-A containing tail to achieve huge amplicon range. To illustrate the method, glioma DNA was compared with white blood cell control DNA of the same patient by means of AluScan. The over 10 Mb sequences obtained, derived from more than 8,000 genes spread over all the chromosomes, revealed a highly reproducible capture of genomic sequences enriched in genic sequences and cancer candidate gene regions. Requiring only sub-micrograms of sample DNA, the power of AluScan as a discovery tool for genetic variations was demonstrated by the identification of 357 instances of loss of heterozygosity, 341 somatic indels, 274 somatic SNVs, and seven potential somatic SNV hotspots between control and glioma DNA.</p> <p>Conclusions</p> <p>AluScan, implemented with just a small number of H-type and T-type inter-Alu PCR primers, provides an effective capture of a diversity of genome-wide sequences for analysis. The method, by enabling an examination of gene-enriched regions containing exons, introns, and intergenic sequences with modest capture and sequencing costs, computation workload and DNA sample requirement is particularly well suited for accelerating the discovery of somatic mutations, as well as analysis of disease-predisposing germline polymorphisms, by making possible the comparative genome-wide scanning of DNA sequences from large human cohorts.</p

Evaluation of the Arabin cervical pessary for prevention of preterm birth in women with a twin pregnancy and short cervix (STOPPIT-2):An open-label randomised trial and updated meta-analysis

BackgroundPreterm-labour-associated preterm birth is a common cause of perinatal mortality and morbidity in twin pregnancy. We aimed to test the hypothesis that the Arabin pessary would reduce preterm-labour-associated preterm birth by 40% or greater in women with a twin pregnancy and a short cervix.Methods and findingsWe conducted an open-label randomised controlled trial in 57 hospital antenatal clinics in the UK and Europe. From 1 April 2015 to 14 February 2019, 2,228 women with a twin pregnancy underwent cervical length screening between 18 weeks 0 days and 20 weeks 6 days of gestation. In total, 503 women with cervical length ≤ 35 mm were randomly assigned to pessary in addition to standard care (n = 250, mean age 32.4 years, mean cervical length 29 mm, with pessary inserted in 230 women [92.0%]) or standard care alone (n = 253, mean age 32.7 years, mean cervical length 30 mm). The pessary was inserted before 21 completed weeks of gestation and removed at between 35 and 36 weeks or before birth if earlier. The primary obstetric outcome, spontaneous onset of labour and birth before 34 weeks 0 days of gestation, was present in 46/250 (18.4%) in the pessary group compared to 52/253 (20.6%) following standard care alone (adjusted odds ratio [aOR] 0.87 [95% CI 0.55-1.38], p = 0.54). The primary neonatal outcome-a composite of any of stillbirth, neonatal death, periventricular leukomalacia, early respiratory morbidity, intraventricular haemorrhage, necrotising enterocolitis, or proven sepsis, from birth to 28 days after the expected date of delivery-was present in 67/500 infants (13.4%) in the pessary group compared to 76/506 (15.0%) following standard care alone (aOR 0.86 [95% CI 0.54-1.36], p = 0.50). The positive and negative likelihood ratios of a short cervix (≤35 mm) to predict preterm birth before 34 weeks were 2.14 and 0.83, respectively. A meta-analysis of data from existing publications (4 studies, 313 women) and from STOPPIT-2 indicated that a cervical pessary does not reduce preterm birth before 34 weeks in women with a short cervix (risk ratio 0.74 [95% CI 0.50-1.11], p = 0.15). No women died in either arm of the study; 4.4% of babies in the Arabin pessary group and 5.5% of babies in the standard treatment group died in utero or in the neonatal period (p = 0.53). Study limitations include lack of power to exclude a smaller than 40% reduction in preterm labour associated preterm birth, and to be conclusive about subgroup analyses.ConclusionsThese results led us to reject our hypothesis that the Arabin pessary would reduce the risk of the primary outcome by 40%. Smaller treatment effects cannot be ruled out.Trial registrationISRCTN Registry ISRCTN 02235181. ClinicalTrials.gov NCT02235181

Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection

Emerging reports of rare neurological complications associated with COVID-19 infection and vaccinations are leading to regulatory, clinical and public health concerns. We undertook a self-controlled case series study to investigate hospital admissions from neurological complications in the 28 days after a first dose of ChAdOx1nCoV-19 (n = 20,417,752) or BNT162b2 (n = 12,134,782), and after a SARS-CoV-2-positive test (n = 2,005,280). There was an increased risk of Guillain–Barré syndrome (incidence rate ratio (IRR), 2.90; 95% confidence interval (CI): 2.15–3.92 at 15–21 days after vaccination) and Bell’s palsy (IRR, 1.29; 95% CI: 1.08–1.56 at 15–21 days) with ChAdOx1nCoV-19. There was an increased risk of hemorrhagic stroke (IRR, 1.38; 95% CI: 1.12–1.71 at 15–21 days) with BNT162b2. An independent Scottish cohort provided further support for the association between ChAdOx1nCoV and Guillain–Barré syndrome (IRR, 2.32; 95% CI: 1.08–5.02 at 1–28 days). There was a substantially higher risk of all neurological outcomes in the 28 days after a positive SARS-CoV-2 test including Guillain–Barré syndrome (IRR, 5.25; 95% CI: 3.00–9.18). Overall, we estimated 38 excess cases of Guillain–Barré syndrome per 10 million people receiving ChAdOx1nCoV-19 and 145 excess cases per 10 million people after a positive SARS-CoV-2 test. In summary, although we find an increased risk of neurological complications in those who received COVID-19 vaccines, the risk of these complications is greater following a positive SARS-CoV-2 test